Eradra5%

Eradra 5% 5% ophthalmic solution is indicated for the treatment of the signs and symptoms of dry eye disease (DED).

Other ophthalmic preparations

Eradra 5% binds to the integrin LFA-1, a cell surface protein found on leukocytes and blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1). ICAM-1 may be overexpressed in corneal and conjunctival tissues in DED. LFA-1/ICAM-1 interaction can contribute to the formation of an immunological synapse resulting in T-cell activation and migration to target tissues. In vitro studies demonstrated that Eradra 5% may inhibit Tcell adhesion to ICAM-1 in a human T-cell line and may inhibit secretion of inflammatory cytokines in human peripheral blood mononuclear cells. The exact mechanism of action of Eradra 5% in DED is not known.

Instill one drop of Eradra 5% twice daily (approximately 12 hours apart) into each eye. Contact lenses should be removed prior to the administration of Eradra 5% and may be reinserted 15 minutes following administration.

Instill one drop of Eradra 5% twice daily (approximately 12 hours apart) into each eye. Contact lenses should be removed prior to the administration of Eradra 5% and may be reinserted 15 minutes following administration.

Patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container.

The common adverse effects are instillation site irritation, dysgeusia and reduced visual acuity. Less common are blurred vision, conjunctival hyperemia, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.

There are no available data on Eradra 5% use in pregnant women to inform any drug associated risks. There are no data on the presence of Eradra 5% in human milk, the effects on the breastfed infant or the effects on milk production.

Do not touch the dropper tip to surfaces since this may contaminate the solution. After one month of the opening do not use the medicine of dropper.

There is no information regarding overdose in patients taking Eradra 5%. For management of a suspected drug overdose, contact your ophthalmologist.

Store in a cool (below 30°C) and dry place, away from light. Keep out of the reach of children.

Pediatric Use: Safety and efficacy in pediatric patients below the age of 17 years have not been established.Geriatric Use: No overall differences in safety or effectiveness have been observed between elderly and younger adult patients.

Other ophthalmic preparations

Eradra 5% binds to the integrin LFA-1, a cell surface protein found on leukocytes and blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1). ICAM-1 may be overexpressed in corneal and conjunctival tissues in DED. LFA-1/ICAM-1 interaction can contribute to the formation of an immunological synapse resulting in T-cell activation and migration to target tissues. In vitro studies demonstrated that Eradra 5% may inhibit Tcell adhesion to ICAM-1 in a human T-cell line and may inhibit secretion of inflammatory cytokines in human peripheral blood mononuclear cells. The exact mechanism of action of Eradra 5% in DED is not known.

There are no available data on Eradra 5% use in pregnant women to inform any drug associated risks. There are no data on the presence of Eradra 5% in human milk, the effects on the breastfed infant or the effects on milk production.

Pediatric Use: Safety and efficacy in pediatric patients below the age of 17 years have not been established.Geriatric Use: No overall differences in safety or effectiveness have been observed between elderly and younger adult patients.